Pharmaguy's Insights Into Drug Industry News
185.9K views | +15 today
Follow
Pharmaguy's Insights Into Drug Industry News
Pharmaguy curates and provides insights into selected drug industry news and issues.
Curated by Pharma Guy
Your new post is loading...
Your new post is loading...
Rescooped by Pharma Guy from Melanoma BRAF Inhibitors Review
Scoop.it!

Can the Cancer 'Moonshot' Succeed with Minimal Funding?

Can the Cancer 'Moonshot' Succeed with Minimal Funding? | Pharmaguy's Insights Into Drug Industry News | Scoop.it
Landmark breakthroughs in cancer treatment and a policy structure where those advances can flourish have given fuel to the ambitious “Moonshot” to cure the disease. But is it really possible?
Via Krishan Maggon
Pharma Guy's insight:

Regardless of the funding, cancer cannot be cured. For more on that, read: “Obama’s Cancer ‘Moonshot’ vs the Catch-22 of Oncology”; http://sco.lt/7G3S5p Meanwhile, “Patient Advocacy Groups Compete for Biden's Cancer ‘Moonshot’ Initiative Funding”; http://sco.lt/6G9oCv

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

Patient Advocacy Groups Compete for Biden's Cancer "Moonshot" Initiative Funding

When Vice President Joe Biden laid out plans for his major cancer research initiative in January, some public health advocates were alarmed. The plan to work toward a cure was ambitious, but there was virtually no mention of the importance of cancer prevention.

 

So in phone calls, meetings, and a public letter to Biden, the advocates delivered the vice president’s team a blunt message: Prevention had to be part of any serious effort to wipe out cancer.

 

By the time the website for Biden’s initiative was launched, it listed vaccines for cancer-causing viruses as a key goal — and said the initiative “seeks to accelerate progress in prevention, diagnosis, and treatment.”

 

It was a case study in influence, and perhaps a testament of what’s to come: a major scramble for attention and clout among cancer advocacy groups.

 

With the Obama administration swinging behind Biden’s “moonshot” effort, and with the National Institutes of Health looking to build on its biggest funding increase in 12 years, cancer advocacy organizations see a window of opportunity to gain additional funding and attention for their respective causes.

 

But if the history of cancer politics in Washington is any guide, the competition will be intense.

 

There are more than 75 cancer advocacy groups that try to make their case in Washington, and while they may share broad goals, scarce resources have long engendered competition among them, fueling tension that is only likely to intensify with more money at stake. Some groups — especially the ones that want to stress prevention and environmental causes of cancer — worry that they’re already getting left behind.

Pharma Guy's insight:

I wonder how much money will actually wind up being spent on "prevention" programs not related to vaccines produced by pharma.

more...
No comment yet.